BCL2 and non-Hodgkin lymphoma: Omari 2011 [28] used the micronucleus test to evaluate micronuclei frequency within the cells, while nested PCR assay was applied by Qaqish 2016 [29] to specifically target the particular biomarker of BCL2-IGH t(14;18) fusion, which is one of the most common chromosomal abnormalities in non-Hodgkin’s lymphoma (NHL).